- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details

Asset Acquisition and License Agreements - Additional Information (Detail) (USD $)	12 Months Ended			1 Months Ended	12 Months Ended		1 Months Ended	12 Months Ended			1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2007 Millennium	Dec. 31, 2009 Millennium	Dec. 31, 2009 Millennium Series C Convertible Preferred Stock	Dec. 31, 2013 Millennium Maximum	Dec. 31, 2011 Astellas Pharma Inc	Dec. 31, 2008 Astellas Pharma Inc	Dec. 31, 2013 Astellas Pharma Inc	Dec. 31, 2013 Astellas Pharma Inc Maximum
Asset Acquisition [Line Items]
License fees paid				$ 5,000,000	$ 250,000			$ 7,200,000	$ 1,000,000
Research and development	79,286,000	49,717,000	46,089,000	5,000,000		250,000		7,200,000
Additional license fees payable on occurrence of specified events							$ 35,000,000				$ 71,500,000
Convertible preferred stock, shares issued as payment						17,667
Issuance of convertible preferred stock, price per share						$ 14.15
Percentage required to pay for any payment received under collaboration excluding royalties										20.00%